Scholarlink

<p>Historically, patients with T-cell acute lymphoblastic leukemia (ALL) had poorer outcomes than those with B-cell ALL. However, with intensive chemotherapy regimens, outcomes for both groups have become similar. From 2002 to 2008, the Japan Association of Childhood Leukemia Study (JACLS) conducted the prospective ALL-02 study, using a unique protocol for T-ALL (T-02). All T-ALL patients received the same induction therapy, and those who had &lt; 25% bone marrow blasts at day 15 and achieved complete remission (CR) after induction continued on the T-02 protocol. Of the 107&#xa0;T-ALL patients enrolled, 98 (91.6%) achieved CR after induction. Among 79 patients continuing on the T-02 protocol, the 2-year event-free survival (EFS), the study’s primary outcome, was 70.9%, with a cumulative incidence of relapse of 29.1% and no observed nonrelapse mortality. Univariate analysis identified female sex as a significant predictor of better EFS. This study suggests that excessive treatment reduction may lead to poorer outcomes, although female patients with a rapid early response could potentially benefit from less-intensive therapy, warranting further investigation in a larger study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of children with T-cell acute lymphoblastic leukemia treated with the JACLS T-02 protocol

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Hisashi Ishida,
  • Souichi Suenobu,
  • Toshihiko Imamura,
  • Takahiro Shiwaku,
  • Suguru Uemura,
  • Takao Deguchi,
  • Takako Miyamura,
  • Koji Kato,
  • Hiroki Hori,
  • Keiko Okada,
  • Hiroshi Tsujimoto,
  • Megumi Oda,
  • Mikiya Endo,
  • Daiichiro Hasegawa,
  • Keiko Yumura-Yagi,
  • Yoshihiro Takahashi,
  • Ikuya Usami,
  • Yoshiyuki Kosaka,
  • Akihiro Iguchi,
  • Hirohide Kawasaki,
  • Atsushi Sato,
  • Junichi Hara,
  • Akiko Moriya-Saito,
  • Keizo Horibe,
  • Yoshiko Hashii

摘要

Historically, patients with T-cell acute lymphoblastic leukemia (ALL) had poorer outcomes than those with B-cell ALL. However, with intensive chemotherapy regimens, outcomes for both groups have become similar. From 2002 to 2008, the Japan Association of Childhood Leukemia Study (JACLS) conducted the prospective ALL-02 study, using a unique protocol for T-ALL (T-02). All T-ALL patients received the same induction therapy, and those who had < 25% bone marrow blasts at day 15 and achieved complete remission (CR) after induction continued on the T-02 protocol. Of the 107 T-ALL patients enrolled, 98 (91.6%) achieved CR after induction. Among 79 patients continuing on the T-02 protocol, the 2-year event-free survival (EFS), the study’s primary outcome, was 70.9%, with a cumulative incidence of relapse of 29.1% and no observed nonrelapse mortality. Univariate analysis identified female sex as a significant predictor of better EFS. This study suggests that excessive treatment reduction may lead to poorer outcomes, although female patients with a rapid early response could potentially benefit from less-intensive therapy, warranting further investigation in a larger study.